PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions: Autoimmune Hemolytic Anemia; Failure of Two Rounds of Treatment Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
British Axial Spondyloarthritis Inception Cohort
Condition: Axial Spondyloarthritis Intervention: Other: No intervenetion Sponsors: The Leeds Teaching Hospitals NHS Trust; Novartis; Pfizer; UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Condition: Relapsed/Refractory Large Granular T Lymphocytic Leukemia Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions: Autoimmune Hemolytic Anemia; Failure of Two Rounds of Treatment Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
British Axial Spondyloarthritis Inception Cohort
Condition: Axial Spondyloarthritis Intervention: Other: No intervenetion Sponsors: The Leeds Teaching Hospitals NHS Trust; Novartis; Pfizer; UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Condition: Relapsed/Refractory Large Granular T Lymphocytic Leukemia Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions: Autoimmune Hemolytic Anemia; Failure of Two Rounds of Treatment Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
British Axial Spondyloarthritis Inception Cohort
Condition: Axial Spondyloarthritis Intervention: Other: No intervenetion Sponsors: The Leeds Teaching Hospitals NHS Trust; Novartis; Pfizer; UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Condition: Relapsed/Refractory Large Granular T Lymphocytic Leukemia Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions: Autoimmune Hemolytic Anemia; Failure of Two Rounds of Treatment Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
British Axial Spondyloarthritis Inception Cohort
Condition: Axial Spondyloarthritis Intervention: Other: No intervenetion Sponsors: The Leeds Teaching Hospitals NHS Trust; Novartis; Pfizer; UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Condition: Relapsed/Refractory Large Granular T Lymphocytic Leukemia Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions: Autoimmune Hemolytic Anemia; Failure of Two Rounds of Treatment Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
British Axial Spondyloarthritis Inception Cohort
Condition: Axial Spondyloarthritis Intervention: Other: No intervenetion Sponsors: The Leeds Teaching Hospitals NHS Trust; Novartis; Pfizer; UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials
